ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

NCT01903330 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma
Gliosarcoma

Interventions

DRUG: ERC1671
DRUG: GM-CSF
DRUG: Cyclophosphamide
DRUG: Oral Control (Sucrose pill)
DRUG: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))
DRUG: Bevacizumab/Bevacizumab Biosimilar

Sponsor

Epitopoietic Research Corporation

Collaborators

[object Object]